



## Announcement on Organizational and Personnel Changes

Osaka, Japan –March 26, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the following organizational and personnel changes, effective April 1, 2018.

### 1. Organizational Changes

“Development QA” is renamed “QA Department”.

※The purpose of the QA Department is to integrate and strengthen the quality assurance (QA) function within the Research and Development division.

### 2. Personnel Changes

#### (1) Executive officer (Effective April 1, 2018)

Name	New Post	Current Post
Kyozo Inari	Executive Officer Supervisor of External Affairs Department	Executive Officer General Manager of External Affairs Department

#### (2) General Managers (Effective April 1, 2018)

Name	New Post	Current Post
Yoshiomi Kunihiro	General Manager of External Affairs Department	Executive Specialist of External Affairs
Tooru Shinki	General Manager of Sapporo Branch	Manager of Sales Section, Tokyo Daini Branch
Yoshiki Ozawa	General Manager of Development Department	Group Manager of Regulatory Affairs Group, Development Department
Hiromu Toyoda	General Manager of QA Department	General Manager of Development QA

**About Sawai**

Founded in 1929, Sawai Pharmaceutical Co., Ltd. has grown into one of the leading generics companies in Japan. Guided by its corporate philosophy, "Patients First," Sawai markets more than 700 high-quality generic products and reliably delivers them to patients throughout Japan. In 2017, Sawai acquired US-based Upsher-Smith Laboratories, LLC marking its first step in overseas expansion to become a globally recognized generic pharmaceutical company. For more information, visit: <https://www.sawai.co.jp/en/>.

**For further information please contact:**

PR/IR group, [pr@sawai.co.jp](mailto:pr@sawai.co.jp)